MedTrace Logo

Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients

NCT00274508 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 261

Last updated 2023-12-01

No results posted yet for this study

Summary

To investigate whether tiotropium (Spiriva) improves exercise endurance in patients with COPD

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

tiotropium bromide

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim Study Coordinator · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-10-10
Primary Completion
2003-01-07

Countries

  • United States
  • Australia
  • Canada
  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00274508 on ClinicalTrials.gov